Moroccan scientist Allal Boutajangout, PhD, and researchers at New York University (NYU) Grossman School of Medicine are expanding Alzheimer’s disease research, with a growing focus on blood biomarkers that could help identify the disease earlier and guide more personalized treatment. Boutajangout said the results showed close associations between blood biomarkers and amyloid and tau deposits detected through PET imaging. Boutajangout said blood biomarkers could help identify disease processes eight to 10 years before major clinical symptoms appear. The work reflects a wider shift in Alzheimer’s research. Thomas Wisniewski, MD, director of the NYU Langone Alzheimer’s Disease Research Center, said researchers ultimately want to identify the specific combination of pathologies affecting each patient.